AcelRx Pharma (ACRX) Tops Q4 EPS by 3c

AcelRx Pharma (NASDAQ: ACRX) reported Q4 EPS of ($0.21), $0.03 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $3.71 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance